ORLANCE
LIVE

Serial Number

90507936

Owner

Orlance, Inc.

Attorney

Connie L. Ellerbach

Filing Date

Feb 3, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ORLANCE Trademark

Serial Number: 90507936 • Registration: 7922033

ORLANCE is a trademark filed by Orlance, Inc. on February 3, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Orlance, Inc. (5 trademarks)

1124 Columbia St., Suite 300
Seattle, WA 98104

Entity Type: 03

Trademark Details

Filing Date

February 3, 2021

Registration Date

August 26, 2025

Published for Opposition

May 3, 2022

Goods & Services

Vaccines; vaccine preparations; medical preparations for the treatment of infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer; pharmaceutical preparations and substances for the treatment of diseases and disorders, namely, infectious diseases, respiratory diseases, mucosal diseases, and cancer; chemical preparations for the treatment of diseases affecting mucosal tissues, the immune system, and respiratory tissues; chemical preparations for pharmaceutical purposes, namely, for, infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer; chemical preparations for medical purposes, namely, for autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer

Medical devices to treat autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes, tumors, and cancer; medical devices for administering vaccines pneumatically and parts thereof; vaccine apparatus comprised of devices for administering vaccines pneumatically; vaccine apparatus, namely, automatic vaccination apparatus

Research and development of vaccines; research and development of medicines, namely pharmaceutical research and development; research and development in the field of vaccination apparatus; medical research; scientific research; clinical research in the field of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes, immunotherapy, immune-oncology, chemotherapy, and anti-tumor agents

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 26, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 26, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 7, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 7, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 5, 2025 SUPC
USE AMENDMENT FILED
Jun 29, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 29, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 2, 2025 EXRA
SOU EXTENSION 5 GRANTED
Apr 1, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 28, 2025 AITU
SOU EXTENSION 5 FILED
Dec 13, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 20, 2024 EXRA
SOU EXTENSION 4 GRANTED
Jun 20, 2024 EX4G
SOU EXTENSION 4 FILED
Jun 20, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2023 EXRA
SOU EXTENSION 3 GRANTED
Dec 19, 2023 EX3G
SOU EXTENSION 3 FILED
Dec 19, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 19, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 22, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jun 20, 2023 EX2G
SOU EXTENSION 2 FILED
Jun 20, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 20, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 23, 2022 EXRA
SOU EXTENSION 1 GRANTED
Dec 21, 2022 EX1G
SOU EXTENSION 1 FILED
Dec 21, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 21, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 28, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 3, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 3, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 13, 2022 NONP
ASSIGNED TO LIE
Mar 27, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 25, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 25, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 25, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 25, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Aug 26, 2021 GNRT
NON-FINAL ACTION WRITTEN
Aug 26, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 25, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2021 NWOS
NEW APPLICATION ENTERED
Feb 6, 2021 NWAP